Roche Holding Ltd

Latest Results (23.10.2025):

In the first half of 2025, Roche Holding Ltd reported robust financial performance, with significant growth in sales and net income. The company demonstrated strong operational efficiency and a solid increase in earnings per share, driven primarily by its Pharmaceuticals division.

Sales Growth

Roche Holding Ltd achieved sales of CHF 30.944 billion in the first half of 2025, reflecting a 7% increase at constant exchange rates (CER) compared to the same period in 2024. The Pharmaceuticals division led this growth with a 10% rise in sales at CER, reaching CHF 24.0 billion.

Core Operating Profit

The core operating profit surged by 11% at CER to CHF 12.010 billion. This increase was driven by strong performance in the Pharmaceuticals sector and effective cost management strategies across the group.

Net Income and Earnings Per Share

Net income attributable to Roche shareholders rose by 25% to CHF 7.410 billion, while diluted earnings per share increased by 18% to CHF 9.23. On a core basis, earnings per share grew by 12% at CER to CHF 11.08, underscoring the company’s enhanced profitability.

Pharmaceuticals Performance

The Pharmaceuticals division experienced a significant boost, with sales up by 10% at CER. Key contributors included Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus, which collectively added CHF 1.7 billion to sales.

Diagnostics Division

Sales in the Diagnostics division remained stable at CHF 7.0 billion. However, the division faced a 14% decline in core operating profit at CER due to increased costs from healthcare pricing reforms in China and higher expenses related to the ramp-up of new products.

Free Cash Flow and Net Debt

Operating free cash flow decreased by 24% to CHF 6.114 billion, primarily due to significant investments and payments related to collaborations. Net debt increased by 21% to CHF (21.005) billion, reflecting the company’s strategic investments and financial commitments.